62 participants
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-12
- Start Date:
- 2023-11-16
- Completion:
- 2025-07-31
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG
No Results Yet